OA10603A - Medicaments - Google Patents

Medicaments Download PDF

Info

Publication number
OA10603A
OA10603A OA60982A OA60982A OA10603A OA 10603 A OA10603 A OA 10603A OA 60982 A OA60982 A OA 60982A OA 60982 A OA60982 A OA 60982A OA 10603 A OA10603 A OA 10603A
Authority
OA
OAPI
Prior art keywords
surfactant
formulation according
integer
médicament
hydrogen
Prior art date
Application number
OA60982A
Other languages
English (en)
Inventor
Li Li-Bovet
Keith Arthur Johnson
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Publication of OA10603A publication Critical patent/OA10603A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
OA60982A 1994-09-28 1997-03-21 Medicaments OA10603A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9419536A GB9419536D0 (en) 1994-09-28 1994-09-28 Medicaments

Publications (1)

Publication Number Publication Date
OA10603A true OA10603A (en) 2002-08-30

Family

ID=10762008

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60982A OA10603A (en) 1994-09-28 1997-03-21 Medicaments

Country Status (32)

Country Link
US (1) US5849265A (fr)
EP (1) EP0783302B1 (fr)
JP (1) JPH10506887A (fr)
KR (1) KR100375469B1 (fr)
CN (1) CN1084614C (fr)
AP (1) AP742A (fr)
AT (1) ATE187063T1 (fr)
AU (1) AU707922B2 (fr)
BG (1) BG62839B1 (fr)
BR (1) BR9509108A (fr)
CZ (1) CZ286356B6 (fr)
DE (1) DE69513671T2 (fr)
DK (1) DK0783302T3 (fr)
EE (1) EE03380B1 (fr)
ES (1) ES2140706T3 (fr)
FI (1) FI971279L (fr)
GB (1) GB9419536D0 (fr)
GE (1) GEP20002140B (fr)
GR (1) GR3032245T3 (fr)
HU (1) HU221856B1 (fr)
IS (1) IS1991B (fr)
MD (1) MD1900C2 (fr)
MX (1) MX9702149A (fr)
NO (1) NO313658B1 (fr)
NZ (1) NZ292995A (fr)
OA (1) OA10603A (fr)
PL (1) PL181453B1 (fr)
RO (1) RO118564B1 (fr)
RU (1) RU2157188C2 (fr)
SK (1) SK281519B6 (fr)
UA (1) UA47412C2 (fr)
WO (1) WO1996009816A1 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410222D0 (en) * 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
US6984404B1 (en) 1998-11-18 2006-01-10 University Of Florida Research Foundation, Inc. Methods for preparing coated drug particles and pharmaceutical formulations thereof
DK1169019T3 (da) * 1999-04-14 2003-06-02 Glaxo Group Ltd Farmaceutisk aerosolformulering
US6406745B1 (en) 1999-06-07 2002-06-18 Nanosphere, Inc. Methods for coating particles and particles produced thereby
GB0009606D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
US6451287B1 (en) 2000-05-26 2002-09-17 Smithkline Beecham Corporation Fluorinated copolymer surfactants and use thereof in aerosol compositions
GB0016876D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Novel formulation
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6858596B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) * 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6858593B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777400B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6750210B2 (en) * 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
SI1775305T1 (sl) * 2000-08-05 2015-01-30 Glaxo Group Limited S-fluorometil ester 6alfa,9alfa-difluoro-17alfa-((2-furanilkarboksil)oksi)- 11beta-hidroksi-16alfa-metil-3-okso-androst-1,4-dien-17-karbotiojske kisline kot protivnetno sredstvo
US7217409B2 (en) 2000-09-22 2007-05-15 Smithkline Beecham Corporation Alkanoic acid derivatives
GB0106046D0 (en) 2001-03-12 2001-05-02 Glaxo Group Ltd Canister
UA77656C2 (en) * 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
KR100831534B1 (ko) * 2001-04-30 2008-05-22 글락소 그룹 리미티드 17.알파 위치에 시클릭 에스테르기를 지닌 항염증성의안드로스탄의 17.베타.-카르보티오에이트 에스테르 유도체
ES2307751T3 (es) * 2001-06-12 2008-12-01 Glaxo Group Limited Nuevos esteres heterociclicos centi-inflamatorios 17 alfa de derivados 17 beta de carbotioato de androstano.
GB0118364D0 (en) * 2001-07-27 2001-09-19 Glaxo Group Ltd Compounds
ES2293157T3 (es) * 2001-08-03 2008-03-16 Glaxo Group Limited Compuestos tensioactivos y uso de los mismos.
GB0125127D0 (en) 2001-10-19 2001-12-12 Glaxo Group Ltd Compounds
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20050175545A1 (en) * 2002-02-04 2005-08-11 Keith Biggadike Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
CA2474626A1 (fr) * 2002-02-13 2003-08-21 Glaxo Group Limited Composes d'acide carboxylique a utiliser comme agents de surface
GB0205327D0 (en) * 2002-03-06 2002-04-17 Glaxo Group Ltd compounds
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
AU2004264941B2 (en) 2003-08-11 2008-11-27 Glaxo Group Limited Pharmaceutical metered dose inhaler and methods relating thereto
EP1658105B1 (fr) 2003-08-29 2018-03-14 Glaxo Group Limited Aerosol-doseur pharmaceutique et procedes associes
US7030255B2 (en) * 2004-03-09 2006-04-18 Lyondell Chemical Technology, L.P. Oxidation process with in-situ H202 generation and polymer-encapsulated catalysts therefor
EP1949891A1 (fr) 2004-10-12 2008-07-30 Generics (UK) Limited Procédé pour la préparation de formules à suspension pour aérosol, caractérisé en ce que les particles soient formées par précipitation à l'intérieur d'un récipient
DE602005009012D1 (de) * 2004-10-12 2008-09-25 Generics Uk Ltd Rmulierungen, worin die partikel durch präzipition in einem aerosolbehälter gebildet werden
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
WO2008097664A1 (fr) 2007-02-11 2008-08-14 Map Pharmaceuticals, Inc. Procédé d'administration thérapeutique de dhe pour procurer un soulagement rapide de la migraine tout en minimisant le profil des effets secondaires
GB0712454D0 (en) * 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5529524A (en) * 1978-08-21 1980-03-01 Toyo Aerosol Kogyo Kk Powdery aerosol composition
US4352789A (en) * 1980-03-17 1982-10-05 Minnesota Mining And Manufacturing Company Aerosol compositions containing finely divided solid materials
GB8501015D0 (en) * 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US4965066A (en) * 1989-06-06 1990-10-23 E. I. Du Pont De Nemours And Company Intranasal administration of 3,3-disubstituted indolines
EP0478686B1 (fr) * 1989-06-22 1993-08-11 Applications Et Transferts De Technologies Avancees Atta Molecules amphiphiliques contenant du fluor et du phosphore, presentant des proprietes tensio-actives
GB8921222D0 (en) * 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
IL97065A (en) * 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
DE4003272A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
DE69131867T2 (de) * 1990-03-23 2000-05-18 Minnesota Mining And Mfg. Co., Saint Paul Anwendung von löslichen fluorhaltigen Tensiden zur Herstellung von Aerosol-Präparaten mit dosierter Abgabe
AU650463B2 (en) * 1990-06-27 1994-06-23 Minnesota Mining And Manufacturing Company The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5126123A (en) * 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations

Also Published As

Publication number Publication date
BR9509108A (pt) 1998-07-14
SK281519B6 (sk) 2001-04-09
EE03380B1 (et) 2001-04-16
EE9700061A (et) 1997-08-15
RU2157188C2 (ru) 2000-10-10
MD1900C2 (ro) 2002-12-31
MX9702149A (es) 1998-04-30
KR970705981A (ko) 1997-11-03
US5849265A (en) 1998-12-15
FI971279A7 (fi) 1997-03-26
CZ93697A3 (en) 1997-08-13
PL181453B1 (pl) 2001-07-31
WO1996009816A1 (fr) 1996-04-04
FI971279A0 (fi) 1997-03-26
FI971279L (fi) 1997-03-26
BG62839B1 (bg) 2000-09-29
BG101347A (en) 1997-12-30
EP0783302A1 (fr) 1997-07-16
MD1900B2 (en) 2002-04-30
NO971422L (no) 1997-05-23
GEP20002140B (en) 2000-06-25
AP742A (en) 1999-04-26
GR3032245T3 (en) 2000-04-27
AP9700951A0 (en) 1997-04-30
IS1991B (is) 2005-02-15
EP0783302B1 (fr) 1999-12-01
PL319342A1 (en) 1997-08-04
CN1168630A (zh) 1997-12-24
DE69513671T2 (de) 2000-04-06
DK0783302T3 (da) 2000-05-29
MD970134A (en) 1999-02-28
GB9419536D0 (en) 1994-11-16
HUT77377A (hu) 1998-04-28
UA47412C2 (uk) 2002-07-15
SK39397A3 (en) 1997-10-08
AU707922B2 (en) 1999-07-22
NO971422D0 (no) 1997-03-25
RO118564B1 (ro) 2003-07-30
DE69513671D1 (de) 2000-01-05
NZ292995A (en) 1998-10-28
IS4438A (is) 1997-03-10
ATE187063T1 (de) 1999-12-15
AU3532195A (en) 1996-04-19
CZ286356B6 (cs) 2000-03-15
KR100375469B1 (ko) 2003-10-17
JPH10506887A (ja) 1998-07-07
HU221856B1 (hu) 2003-02-28
ES2140706T3 (es) 2000-03-01
CN1084614C (zh) 2002-05-15
NO313658B1 (no) 2002-11-11

Similar Documents

Publication Publication Date Title
OA10603A (en) Medicaments
EP0616525B1 (fr) Formulation d'aerosol pharmaceutique
US5955439A (en) Pharmaceutical aerosol containing at least one sugar
AP419A (en) Pharmaceutical aerosol formulation comprising beclomethasone diproprionate monohydrate.
US6333023B1 (en) Aerosol formulation containing particulate formoterol, propellant and polar cosolvent
EP0990437A1 (fr) Compositions pharmaceutiques sous forme d'aérosol
AU4705093A (en) Surfactant free aerosol formulations containing beclomethasone dipropionate
CA2200986C (fr) Medicaments
CA2141039C (fr) Formulations d'aerosol exemptes de surfactif, renfermant du dipropionate de beclomethasone
HK1009588B (en) Pharmaceutical aerosol formulations comprising beclomethasone dipropionate
HK1111611A (en) Medicaments